WO2021022447A1 - Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp - Google Patents

Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp Download PDF

Info

Publication number
WO2021022447A1
WO2021022447A1 PCT/CN2019/099279 CN2019099279W WO2021022447A1 WO 2021022447 A1 WO2021022447 A1 WO 2021022447A1 CN 2019099279 W CN2019099279 W CN 2019099279W WO 2021022447 A1 WO2021022447 A1 WO 2021022447A1
Authority
WO
WIPO (PCT)
Prior art keywords
tcr
chain
amino acid
seq
variable domain
Prior art date
Application number
PCT/CN2019/099279
Other languages
English (en)
Chinese (zh)
Inventor
李懿
胡静
相瑞瑞
孙含丽
Original Assignee
广东香雪精准医疗技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东香雪精准医疗技术有限公司 filed Critical 广东香雪精准医疗技术有限公司
Priority to PCT/CN2019/099279 priority Critical patent/WO2021022447A1/fr
Publication of WO2021022447A1 publication Critical patent/WO2021022447A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to TCRs capable of recognizing short peptides derived from AFP antigens.
  • the present invention also relates to AFP-specific T cells obtained by transducing the above TCRs, and their use in the prevention and treatment of AFP-related diseases.
  • AFP ( ⁇ Fetoprotein), also known as ⁇ fetoprotein, is a protein expressed during embryonic development and the main component of embryonic serum. During development, AFP has a relatively high expression level in the yolk sac and liver, and is subsequently inhibited. In hepatocellular carcinoma, the expression of AFP is activated (Butterfield et al. J Immunol., 2001, Apr 15; 166(8): 5300-8). After AFP is produced in the cell, it is degraded into small molecule polypeptides, and combined with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface.
  • FMNKFIYEI (SEQ ID NO: 9) is a short peptide derived from AFP antigen and a target for the treatment of AFP-related diseases.
  • T cell adoptive immunotherapy is the transfer of reactive T cells specific to target cell antigens into the patient's body so that they can act against the target cells.
  • T cell receptor TCR
  • T cell receptor is a membrane protein on the surface of T cells, which can recognize short antigen peptides on the surface of corresponding target cells.
  • pMHC complex short peptide-major histocompatibility complex
  • APC antigen-presenting cells
  • T cells and The other cell membrane surface molecules of the two APCs interact, causing a series of subsequent cell signal transmission and other physiological reactions, so that T cells with different antigen specificities can exert immune effects on their target cells.
  • those skilled in the art are dedicated to isolating TCRs specific to AFP antigen short peptides, and transducing the TCR to T cells to obtain T cells specific to AFP antigen short peptides, so that they can be used in cellular immunotherapy. Play a role.
  • the purpose of the present invention is to provide a T cell receptor that recognizes short peptides of AFP antigen.
  • the first aspect of the present invention provides a T cell receptor (TCR) that can bind to the FMNKFIYEI-HLA A0201 complex.
  • the TCR comprises a TCR ⁇ chain variable domain and a TCR ⁇ chain variable domain
  • the amino acid sequence of CDR3 of the TCR ⁇ chain variable domain is ATDEANDYKLS (SEQ ID NO: 12); and/or the The amino acid sequence of CDR3 of the TCR ⁇ chain variable domain is ASRGIGDAGELF (SEQ ID NO: 15).
  • the three complementarity determining regions (CDRs) of the TCR ⁇ chain variable domain are:
  • the three complementarity determining regions of the TCR ⁇ chain variable domain are:
  • the TCR comprises a TCR ⁇ chain variable domain and a TCR ⁇ chain variable domain
  • the TCR ⁇ chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO:1; and/ Or the TCR ⁇ chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 5.
  • the TCR comprises an alpha chain variable domain amino acid sequence SEQ ID NO:1.
  • the TCR comprises the ⁇ -chain variable domain amino acid sequence SEQ ID NO: 5.
  • the TCR is an ⁇ heterodimer, which comprises a TCR ⁇ chain constant region TRAC*01 and a TCR ⁇ chain constant region TRBC1*01 or TRBC2*01.
  • the alpha chain amino acid sequence of the TCR is SEQ ID NO: 3 and/or the beta chain amino acid sequence of the TCR is SEQ ID NO: 7.
  • the TCR is soluble.
  • the TCR is single-stranded.
  • the TCR is formed by linking the ⁇ chain variable domain and the ⁇ chain variable domain through a peptide linking sequence.
  • the TCR is at the 11th, 13th, 19th, 21st, 53, 76, 89, 91, or 94th amino acid positions of the ⁇ chain variable region, and/or the reciprocal of the ⁇ chain J gene short peptide amino acid There are one or more mutations in position 3, position 5, or position 7; and/or the TCR has amino acids 11, 13, 19, 21, 53, 76, 89, 91 in the ⁇ chain variable region , Or position 94, and/or ⁇ -chain J gene short peptide amino acid in the penultimate position 2, the last 4 position or the last 6 position has one or more mutations, wherein the amino acid position number is according to IMGT (International Immunogenetics Information) The position number listed in the system).
  • IMGT International Immunogenetics Information
  • amino acid sequence of the alpha chain variable domain of the TCR comprises SEQ ID NO: 32 and/or the amino acid sequence of the beta chain variable domain of the TCR comprises SEQ ID NO: 34.
  • amino acid sequence of the TCR is SEQ ID NO: 30.
  • the TCR includes (a) all or part of the TCR ⁇ chain except the transmembrane domain; and (b) all or part of the TCR ⁇ chain except the transmembrane domain;
  • (a) and (b) each comprise a functional variable domain, or comprise a functional variable domain and at least a part of the constant domain of the TCR chain.
  • cysteine residues form an artificial disulfide bond between the constant domains of the ⁇ and ⁇ chains of the TCR.
  • cysteine residues forming artificial disulfide bonds in the TCR are substituted with one or more groups selected from the following:
  • the alpha chain amino acid sequence of the TCR is SEQ ID NO: 26 and/or the beta chain amino acid sequence of the TCR is SEQ ID NO: 28.
  • the alpha chain variable region and the beta chain constant region of the TCR contain artificial interchain disulfide bonds.
  • cysteine residues forming the artificial interchain disulfide bond in the TCR are substituted with one or more groups selected from the following:
  • the TCR includes an ⁇ chain variable domain and a ⁇ chain variable domain, and all or part of the ⁇ chain constant domain except the transmembrane domain, but it does not include the ⁇ chain constant domain.
  • the ⁇ chain variable domain and ⁇ chain form a heterodimer.
  • a conjugate is bound to the C- or N-terminus of the ⁇ chain and/or ⁇ chain of the TCR.
  • the conjugate that binds to the T cell receptor is a detectable marker, a therapeutic agent, a PK modified part or a combination of any of these substances.
  • the therapeutic agent is an anti-CD3 antibody.
  • the second aspect of the present invention provides a multivalent TCR complex comprising at least two TCR molecules, and at least one of the TCR molecules is the TCR described in the first aspect of the present invention.
  • the third aspect of the present invention provides a nucleic acid molecule, which comprises a nucleic acid sequence encoding the TCR molecule of the first aspect of the present invention or its complement.
  • the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 2 or SEQ ID NO: 33 encoding the variable domain of the TCR ⁇ chain.
  • the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 6 or SEQ ID NO: 35 encoding the variable domain of the TCR ⁇ chain.
  • the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 4 encoding the TCR ⁇ chain and/or the nucleotide sequence SEQ ID NO: 8 encoding the TCR ⁇ chain.
  • the fourth aspect of the present invention provides a vector containing the nucleic acid molecule described in the third aspect of the present invention; preferably, the vector is a viral vector; more preferably, the vector is a slow Viral vector.
  • the fifth aspect of the present invention provides an isolated host cell containing the vector according to the fourth aspect of the present invention or the exogenous nucleic acid molecule according to the third aspect of the present invention integrated into the genome .
  • the sixth aspect of the present invention provides a cell that transduces the nucleic acid molecule of the third aspect of the present invention or the vector of the fourth aspect of the present invention; preferably, the cell is a T cell or a stem cell .
  • the seventh aspect of the present invention provides a pharmaceutical composition containing a pharmaceutically acceptable carrier and the TCR according to the first aspect of the present invention, the TCR complex according to the second aspect of the present invention, and the The nucleic acid molecule according to the third aspect of the invention, the vector according to the fourth aspect of the invention, or the cell according to the sixth aspect of the invention.
  • the eighth aspect of the present invention provides the T cell receptor according to the first aspect of the present invention, or the TCR complex according to the second aspect of the present invention, the nucleic acid molecule according to the third aspect of the present invention, and the fourth aspect of the present invention.
  • the use of the vector described in the aspect or the cell described in the sixth aspect of the present invention is used to prepare a medicine for treating tumors or autoimmune diseases.
  • the ninth aspect of the present invention provides a method for treating diseases, comprising administering an appropriate amount of the T cell receptor according to the first aspect of the present invention or the TCR complex according to the second aspect of the present invention to a subject in need of treatment ,
  • the disease is a tumor, preferably the tumor is hepatocellular carcinoma.
  • Figure 1a, Figure 1b, Figure 1c, Figure 1d, Figure 1e and Figure 1f are the TCR ⁇ chain variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, The amino acid sequence of the TCR ⁇ chain of the leader sequence and the nucleotide sequence of the TCR ⁇ chain with the leader sequence.
  • Figure 2a, Figure 2b, Figure 2c, Figure 2d, Figure 2e and Figure 2f are the TCR ⁇ chain variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, The amino acid sequence of the TCR ⁇ chain of the leader sequence and the nucleotide sequence of the TCR ⁇ chain with the leader sequence.
  • Figure 3 shows the CD8 + and tetramer-PE double positive staining results of monoclonal cells.
  • Figure 4a and Figure 4b are the amino acid sequence and nucleotide sequence of the soluble TCR ⁇ chain, respectively.
  • Figures 5a and 5b show the amino acid sequence and nucleotide sequence of the soluble TCR ⁇ chain, respectively.
  • Figure 6 is a gel image of the soluble TCR obtained after purification.
  • the leftmost lane is reducing glue
  • the middle lane is molecular weight markers
  • the rightmost lane is non-reducing glue.
  • Figure 7a and Figure 7b are the amino acid sequence and nucleotide sequence of the single-stranded TCR, respectively.
  • Figure 8a and Figure 8b are the amino acid sequence and nucleotide sequence of the variable domain of the single-chain TCR ⁇ chain, respectively.
  • Figures 9a and 9b are the amino acid sequence and nucleotide sequence of the variable domain of the single-stranded TCR ⁇ chain, respectively.
  • Figures 10a and 10b are the amino acid sequence and nucleotide sequence of the single-stranded TCR linker, respectively.
  • Figure 11 is a gel image of a soluble single-chain TCR obtained after purification.
  • the left lane is a molecular weight marker, and the right lane is non-reducing gel.
  • Figure 12 is a BIAcore kinetic map of the combination of soluble TCR and FMNKFIYEI-HLA A0201 complex of the present invention.
  • Figure 13 is a BIAcore kinetic map of the combination of soluble single-chain TCR of the present invention and FMNKFIYEI-HLA A0201 complex.
  • Figure 14 shows the result of the ELISPOT activation function verification of the obtained T cell clone.
  • FIG. 15 shows the results of the activation experiment of T cells transduced with TCR of the present invention on T2 loaded target cells.
  • Figure 16 is a diagram showing the results of the Elispot activation experiment on tumor cell lines by T cells transduced with the TCR of the present invention.
  • the present invention also provides a nucleic acid molecule encoding the TCR and a vector containing the nucleic acid molecule.
  • the present invention also provides cells for transducing the TCR of the present invention.
  • MHC molecules are proteins of the immunoglobulin superfamily, and can be class I or class II MHC molecules. Therefore, it is specific for the presentation of antigens. Different individuals have different MHCs and can present different short peptides in a protein antigen to the surface of their respective APC cells. Human MHC is usually called HLA gene or HLA complex.
  • T cell receptor is the only receptor for specific antigen peptides presented on the main histocompatibility complex (MHC).
  • MHC main histocompatibility complex
  • APC antigen-presenting cells
  • T cells with different antigen specificities exert immune effects on their target cells.
  • TCR is a glycoprotein on the cell membrane surface that is composed of ⁇ chain/ ⁇ chain or ⁇ chain/ ⁇ chain in the form of heterodimer.
  • TCR heterodimers consist of ⁇ and ⁇ chains, while 5% of T cells have TCRs consisting of ⁇ and ⁇ chains.
  • Natural ⁇ heterodimeric TCR has ⁇ chain and ⁇ chain, and ⁇ chain and ⁇ chain constitute subunits of ⁇ heterodimeric TCR.
  • each chain of ⁇ and ⁇ includes a variable region, a connecting region and a constant region.
  • the ⁇ chain usually also contains a short variable region between the variable region and the connecting region, but the variable region is often regarded as the connecting region. a part of.
  • Each variable region contains 3 CDRs (complementarity determining regions), CDR1, CDR2, and CDR3, which are embedded in framework regions.
  • the CDR region determines the combination of TCR and pMHC complex, where CDR3 is recombined from the variable region and the connecting region, and is called the hypervariable region.
  • the ⁇ and ⁇ chains of TCR are generally regarded as having two "domains" each, namely a variable domain and a constant domain.
  • the variable domain is composed of a connected variable region and a connecting region.
  • the sequence of the constant domain of TCR can be found in the public database of the International Immunogenetics Information System (IMGT).
  • IMGT International Immunogenetics Information System
  • the sequence of the constant domain of the ⁇ chain of the TCR molecule is "TRAC*01”
  • the sequence of the constant domain of the ⁇ chain of the TCR molecule is "TRBC1*" 01" or "TRBC2*01”.
  • the ⁇ and ⁇ chains of TCR also contain transmembrane and cytoplasmic regions, which are very short.
  • polypeptide of the present invention TCR of the present invention
  • T cell receptor of the present invention T cell receptor of the present invention
  • the position numbers of the amino acid sequence of TRAC*01 and TRBC1*01 or TRBC2*01 in the present invention are numbered in sequence from N-terminal to C-terminal, such as TRBC1*01 or TRBC2*01
  • the 60th amino acid is P (proline)
  • Pro60 of TRBC1*01 or TRBC2*01 exon 1 in the present invention or It is expressed as the 60th amino acid of TRBC1*01 or TRBC2*01 exon 1.
  • the 61st amino acid is Q(glutamine) in sequence from N to C.
  • Amide in the present invention, it can be described as Gln61 of TRBC1*01 or TRBC2*01 exon 1, or it can be expressed as the 61st amino acid of TRBC1*01 or TRBC2*01 exon 1, other And so on.
  • the position numbers of the amino acid sequences of TRAV and TRBV in the variable regions are numbered according to the position numbers listed in IMGT. For example, for a certain amino acid in TRAV, the position number listed in IMGT is 46, then it is described as the 46th amino acid of TRAV in the present invention, and so on. In the present invention, if the sequence position numbers of other amino acids have special instructions, follow the special instructions.
  • the antigen In the process of antigen processing, the antigen is degraded inside the cell and then carried to the cell surface by MHC molecules. T cell receptors can recognize peptide-MHC complexes on the surface of antigen-presenting cells. Therefore, the first aspect of the present invention provides a TCR molecule capable of binding to the FMNKFIYEI-HLA A0201 complex. Preferably, the TCR molecule is isolated or purified. The ⁇ and ⁇ chains of the TCR each have three complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • the ⁇ chain of the TCR includes a CDR having the following amino acid sequence:
  • the three complementarity determining regions of the TCR ⁇ chain variable domain are:
  • the above amino acid sequence of the CDR region of the present invention can be embedded into any suitable framework structure to prepare a chimeric TCR.
  • the framework structure is compatible with the CDR regions of the TCR of the present invention, those skilled in the art can design or synthesize TCR molecules with corresponding functions based on the CDR regions disclosed in the present invention. Therefore, the TCR molecule of the present invention refers to a TCR molecule comprising the above-mentioned ⁇ and/or ⁇ chain CDR region sequence and any suitable framework structure.
  • the TCR ⁇ chain variable domain of the present invention is an amino acid sequence that has at least 90%, preferably 95%, more preferably 98% sequence identity with SEQ ID NO:1; and/or the TCR ⁇ chain variable domain of the present invention is the same as SEQ ID NO:5 has an amino acid sequence with at least 90%, preferably 95%, more preferably 98% sequence identity.
  • the TCR molecule of the present invention is a heterodimer composed of ⁇ and ⁇ chains.
  • the ⁇ chain of the heterodimeric TCR molecule includes a variable domain and a constant domain, and the amino acid sequence of the ⁇ chain variable domain includes the CDR1 (SEQ ID NO: 10) and CDR2 (SEQ ID NO: 10) of the above ⁇ chain. ID NO: 11) and CDR3 (SEQ ID NO: 12).
  • the TCR molecule comprises an alpha chain variable domain amino acid sequence SEQ ID NO:1. More preferably, the alpha chain variable domain amino acid sequence of the TCR molecule is SEQ ID NO:1.
  • the ⁇ chain of the heterodimeric TCR molecule includes a variable domain and a constant domain
  • the amino acid sequence of the ⁇ chain variable domain includes CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO: 14) and CDR3 (SEQ ID NO: 15).
  • the TCR molecule comprises the beta chain variable domain amino acid sequence SEQ ID NO: 5. More preferably, the amino acid sequence of the ⁇ chain variable domain of the TCR molecule is SEQ ID NO: 5.
  • the TCR molecule of the present invention is a single-stranded TCR molecule composed of part or all of the alpha chain and/or part or all of the beta chain.
  • single-chain TCR molecules please refer to Chung et al (1994) Proc. Natl. Acad. Sci. USA 91, 12654-12658. According to the literature, those skilled in the art can easily construct single-chain TCR molecules containing the CDRs of the present invention.
  • the single-stranded TCR molecule comprises V ⁇ , V ⁇ and C ⁇ , and is preferably connected in order from N-terminal to C-terminal.
  • the alpha chain variable domain amino acid sequence of the single-chain TCR molecule includes CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the aforementioned ⁇ chain.
  • the single-chain TCR molecule comprises an ⁇ -chain variable domain amino acid sequence SEQ ID NO:1. More preferably, the alpha chain variable domain amino acid sequence of the single-chain TCR molecule is SEQ ID NO:1.
  • the ⁇ -chain variable domain amino acid sequence of the single-chain TCR molecule includes CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO: 14), and CDR3 (SEQ ID NO: 15) of the ⁇ -chain.
  • the single-chain TCR molecule comprises the ⁇ -chain variable domain amino acid sequence SEQ ID NO: 5. More preferably, the ⁇ -chain variable domain amino acid sequence of the single-chain TCR molecule is SEQ ID NO: 5.
  • the constant domain of the TCR molecule of the present invention is a human constant domain.
  • the constant domain sequence of the alpha chain of the TCR molecule of the present invention can be "TRAC*01”
  • the constant domain sequence of the beta chain of the TCR molecule can be "TRBC1*01” or "TRBC2*01”.
  • the 53rd position of the amino acid sequence given in IMGT's TRAC*01 is Arg, which is represented here as: Arg53 of TRAC*01 exon 1, and so on.
  • the amino acid sequence of the ⁇ chain of the TCR molecule of the present invention is SEQ ID NO: 3, and/or the amino acid sequence of the ⁇ chain is SEQ ID NO: 7.
  • TCR The naturally occurring TCR is a membrane protein that is stabilized by its transmembrane domain. Like immunoglobulins (antibodies) as antigen recognition molecules, TCRs can also be developed for diagnosis and treatment, and soluble TCR molecules need to be obtained.
  • the soluble TCR molecule does not include its transmembrane region. Soluble TCR has a wide range of uses. It can be used not only to study the interaction between TCR and pMHC, but also as a diagnostic tool for detecting infection or as a marker for autoimmune diseases.
  • soluble TCR can be used to deliver therapeutic agents (such as cytotoxic compounds or immunostimulatory compounds) to cells that present specific antigens.
  • soluble TCR can also bind to other molecules (such as anti-CD3 antibodies). To redirect T cells to target cells that present specific antigens.
  • the present invention also obtains the soluble TCR specific to the AFP antigen short peptide.
  • the TCR of the present invention may be a TCR with artificial disulfide bonds introduced between the residues of the constant domains of its ⁇ and ⁇ chains.
  • Cysteine residues form artificial interchain disulfide bonds between the alpha and beta chain constant domains of the TCR.
  • Cysteine residues can be substituted for other amino acid residues at appropriate positions in the natural TCR to form artificial interchain disulfide bonds. For example, replace Thr48 of TRAC*01 exon 1 and replace the cysteine residue of Ser57 of TRBC1*01 or TRBC2*01 exon 1 to form a disulfide bond.
  • Other sites for introducing cysteine residues to form disulfide bonds can also be: Thr45 of TRAC*01 exon 1 and TRBC1*01 or Ser77 of TRBC2*01 exon 1; TRAC*01 exon Tyr10 of 1 and Ser17 of TRBC1*01 or TRBC2*01 exon 1; Thr45 of TRAC*01 exon 1 and Asp59 of TRBC1*01 or TRBC2*01 exon 1; TRAC*01 exon 1 Ser15 and TRBC1*01 or TRBC2*01 exon 1 Glu15; TRAC*01 exon 1 Arg53 and TRBC1*01 or TRBC2*01 exon 1 Ser54; TRAC*01 exon 1 Pro89 and Ala19 of TRBC1*01 or TRBC2*01 exon 1; or Tyr10 of TRAC*01 exon 1 and Glu20 of TRBC1*01 or TRBC2*01 exon 1.
  • cysteine residues replace any set of positions in the constant domains of the ⁇ and ⁇ chains.
  • a maximum of 50, or a maximum of 30, or a maximum of 15, or a maximum of 10, or a maximum of 8 or less amino acids can be truncated at one or more C-termini of the TCR constant domain of the present invention, so that it does not include Cysteine residues can be used to delete natural disulfide bonds, and the cysteine residues that form natural disulfide bonds can be mutated to another amino acid to achieve the above purpose.
  • the TCR of the present invention may contain artificial disulfide bonds introduced between the residues of the constant domains of its ⁇ and ⁇ chains. It should be noted that, with or without the introduced artificial disulfide bonds between the constant domains, the TCR of the present invention can contain the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence.
  • the TRAC constant domain sequence of TCR and the TRBC1 or TRBC2 constant domain sequence can be linked by natural disulfide bonds present in the TCR.
  • the TCR of the present invention also includes a TCR that has mutations in its hydrophobic core region.
  • These mutations in the hydrophobic core region are preferably mutations that can improve the stability of the soluble TCR of the present invention, as described in Publication No. It is described in the patent document of WO2014/206304.
  • TCR can be mutated at the following variable domain hydrophobic core positions: ( ⁇ and/or ⁇ chain) variable region amino acid positions 11, 13, 19, 21, 53, 76, 89, 91, 94, and/ Or alpha chain J gene (TRAJ) short peptide amino acid position is the 3rd, 5th, and 7th position from the bottom, and/or ⁇ chain J gene (TRBJ) short peptide amino acid position is the 2nd, 4th, 6th position from the bottom, the position number of the amino acid sequence According to the position number listed in the International Immunogenetics Information System (IMGT).
  • IMGT International Immunogenetics Information System
  • the TCR in which the hydrophobic core region is mutated may be a stable soluble single-chain TCR composed of a flexible peptide chain connecting the variable domains of the ⁇ and ⁇ chains of the TCR.
  • the flexible peptide chain in the present invention can be any peptide chain suitable for connecting the variable domains of the TCR ⁇ and ⁇ chains.
  • the alpha chain variable domain amino acid sequence is SEQ ID NO: 32
  • the encoded nucleotide sequence is SEQ ID NO: 33
  • ⁇ chain variable domain amino acid sequence It is SEQ ID NO: 34
  • the encoded nucleotide sequence is SEQ ID NO: 35.
  • Patent Document 201510260322.4 also discloses that the introduction of artificial interchain disulfide bonds between the ⁇ chain variable region and the ⁇ chain constant region of the TCR can significantly improve the stability of the TCR. Therefore, the high-affinity TCR of the present invention may also contain artificial interchain disulfide bonds between the ⁇ chain variable region and the ⁇ chain constant region.
  • cysteine residue that forms an artificial interchain disulfide bond between the ⁇ chain variable region and the ⁇ chain constant region of the TCR is substituted: the 46th amino acid of TRAV and TRBC1*01 or TRBC2* The 60th amino acid of 01 exon 1; the 47th amino acid of TRAV and the 61st amino acid of TRBC1*01 or TRBC2*01 exon 1; the 46th amino acid of TRAV and the TRBC1*01 or TRBC2*01 exon The 61st amino acid of sub 1; or the 47th amino acid of TRAV and the 60th amino acid of TRBC1*01 or TRBC2*01 exon 1.
  • such a TCR may comprise (i) all or part of the TCR ⁇ chain excluding its transmembrane domain, and (ii) all or part of the TCR ⁇ chain excluding its transmembrane domain, wherein (i) and (ii) ) Contains the variable domain and at least a part of the constant domain of the TCR chain, and the ⁇ chain and the ⁇ chain form a heterodimer. More preferably, such a TCR may include an ⁇ chain variable domain and a ⁇ chain variable domain and all or part of the ⁇ chain constant domain except the transmembrane domain, but it does not include the ⁇ chain constant domain. The chain variable domain and the ⁇ chain form a heterodimer.
  • the TCR of the present invention can also be provided in the form of a multivalent complex.
  • the multivalent TCR complex of the present invention contains two, three, four or more TCRs of the present invention combined to form a polymer.
  • the tetramerization domain of p53 can be used to generate a tetramer, or more A complex formed by combining the TCR of the present invention with another molecule.
  • the TCR complex of the present invention can be used to track or target cells presenting a specific antigen in vitro or in vivo, and can also be used to produce intermediates of other multivalent TCR complexes with such applications.
  • the TCR of the present invention can be used alone or combined with the conjugate in a covalent or other manner, preferably in a covalent manner.
  • the conjugate includes a detectable marker (for diagnostic purposes, the TCR is used to detect the presence of cells presenting the FMNKFIYEI-HLA A0201 complex), a therapeutic agent, a PK (protein kinase) modified portion or any of the above substances The combination of binding or coupling.
  • Detectable markers used for diagnostic purposes include, but are not limited to: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (electronic computer tomography) contrast agents, or capable of producing detectable products Of enzymes.
  • Therapeutic agents that can be combined or coupled with the TCR of the present invention include but are not limited to: 1. Radionuclides (Koppe et al., 2005, Cancer metastasis reviews 24, 539); 2. Biotoxicity (Chaudhary et al., 1989) , Nature 339,394; Epel et al., 2002, Cancer Immunology and Immunotherapy (Cancer Immunology and Immunotherapy 51,565); 3. Cytokines such as IL-2, etc.
  • Gold nanoparticles/nano Stick (Lapotko et al., 2005, Cancer letters 239, 36; Huang et al., 2006, Journal of the American Chemical Society 128, 2115); 7. Virus particles (Peng et al., 2004, Gene Treatment (Genetherapy) 11, 1234); 8. Liposomes (Mamot et al., 2005, Cancer research (Cancer research) 65, 11631); 9. Nano magnetic particles; 10. Prodrug activating enzymes (for example, DT-cardiac Diazyme (DTD) or biphenyl hydrolase-like protein (BPHL)); 11. Chemotherapeutics (for example, cisplatin) or any form of nanoparticles, etc.
  • DTD DT-cardiac Diazyme
  • BPHL biphenyl hydrolase-like protein
  • the TCR of the present invention may also be a hybrid TCR containing sequences derived from more than one species.
  • the TCR of the present invention may include a human variable domain and a murine constant domain. The disadvantage of this method is that it may trigger an immune response. Therefore, when it is used in adoptive T cell therapy, there should be a regulatory scheme for immunosuppression to allow the implantation of T cells expressing murine.
  • the second aspect of the present invention provides a nucleic acid molecule encoding a TCR molecule of the first aspect of the present invention or a part thereof, which may be one or more CDRs, variable domains of ⁇ and/or ⁇ chains, and ⁇ chains and/ Or beta chain.
  • nucleotide sequence encoding the ⁇ chain CDR region of the TCR molecule of the first aspect of the present invention is as follows:
  • nucleotide sequence encoding the ⁇ chain CDR region of the TCR molecule of the first aspect of the present invention is as follows:
  • the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain of the present invention includes SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, and/or the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain of the present invention.
  • the nucleotide sequence includes SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21.
  • the nucleotide sequence of the nucleic acid molecule of the present invention may be single-stranded or double-stranded, the nucleic acid molecule may be RNA or DNA, and may or may not contain introns.
  • the nucleotide sequence of the nucleic acid molecule of the present invention does not contain introns but can encode the polypeptide of the present invention.
  • the nucleotide sequence of the nucleic acid molecule of the present invention encoding the variable domain of the TCR ⁇ chain of the present invention includes SEQ ID NO: 2 and /Or the nucleotide sequence of the nucleic acid molecule of the present invention encoding the variable domain of the TCR ⁇ chain of the present invention includes SEQ ID NO: 6.
  • the nucleotide sequence of the nucleic acid molecule of the present invention encoding the TCR ⁇ chain variable domain of the present invention includes SEQ ID NO: 33 and/or the nucleotide sequence of the nucleic acid molecule encoding the TCR ⁇ chain variable domain of the present invention includes SEQ ID NO: 35. More preferably, the nucleotide sequence of the nucleic acid molecule of the present invention comprises SEQ ID NO: 4 and/or SEQ ID NO: 8. Alternatively, the nucleotide sequence of the nucleic acid molecule of the present invention is SEQ ID NO: 31.
  • nucleic acid sequence encoding the TCR of the present invention may be the same as the nucleic acid sequence shown in the drawings of the present invention or a degenerate variant. Taking one of the examples in the present invention to illustrate, "degenerate variant” refers to a nucleic acid sequence that encodes a protein sequence of SEQ ID NO: 1, but is different from the sequence of SEQ ID NO: 2.
  • the nucleotide sequence can be codon optimized. Different cells use specific codons differently. According to the cell type, the codons in the sequence can be changed to increase the amount of expression. Codon usage tables for mammalian cells and many other organisms are well known to those skilled in the art.
  • the full-length sequence of the nucleic acid molecule of the present invention or its fragments can usually be obtained by but not limited to PCR amplification method, recombination method or artificial synthesis method.
  • the DNA sequence encoding the TCR (or a fragment or derivative thereof) of the present invention can be obtained completely through chemical synthesis.
  • the DNA sequence can then be introduced into various existing DNA molecules (or such as vectors) and cells known in the art.
  • DNA can be a coding strand or a non-coding strand.
  • the present invention also relates to vectors containing the nucleic acid molecules of the present invention, including expression vectors, that is, constructs capable of expression in vivo or in vitro.
  • expression vectors include bacterial plasmids, bacteriophages, and animal and plant viruses.
  • Viral delivery systems include but are not limited to adenovirus vectors, adeno-associated virus (AAV) vectors, herpes virus vectors, retrovirus vectors, lentivirus vectors, and baculovirus vectors.
  • AAV adeno-associated virus
  • the vector can transfer the nucleotide of the present invention into a cell, such as a T cell, so that the cell expresses a TCR specific for the AFP antigen.
  • a cell such as a T cell
  • the vector should be able to continuously express at a high level in T cells.
  • the present invention also relates to a host cell produced by genetic engineering using the vector or coding sequence of the present invention.
  • the host cell contains the vector of the present invention or the nucleic acid molecule of the present invention is integrated into the chromosome.
  • the host cell is selected from: prokaryotic cells and eukaryotic cells, such as E. coli, yeast cells, CHO cells and the like.
  • the present invention also includes isolated cells expressing the TCR of the present invention, especially T cells.
  • the T cells may be derived from T cells isolated from the subject, or may be a mixed cell population isolated from the subject, such as part of a peripheral blood lymphocyte (PBL) population.
  • PBL peripheral blood lymphocyte
  • the cells can be isolated from peripheral blood mononuclear cells (PBMC), and can be CD4 + helper T cells or CD8 + cytotoxic T cells.
  • PBMC peripheral blood mononuclear cells
  • the cells can be in a mixed population of CD4 + helper T cells/CD8 + cytotoxic T cells.
  • the cells can be activated with antibodies (eg, anti-CD3 or anti-CD28 antibodies) so that they can be more easily transfected, for example, with a vector containing a nucleotide sequence encoding the TCR molecule of the present invention. dye.
  • antibodies eg, anti-CD3 or anti-CD28 antibodies
  • the cells of the present invention can also be or derived from stem cells, such as hematopoietic stem cells (HSC).
  • stem cells such as hematopoietic stem cells (HSC).
  • HSC hematopoietic stem cells
  • T cell transfection with DNA or RNA encoding the TCR of the present invention There are many methods suitable for T cell transfection with DNA or RNA encoding the TCR of the present invention (eg, Robbins et al., (2008) J. Immunol. 180: 6116-6131). T cells expressing the TCR of the present invention can be used for adoptive immunotherapy. Those skilled in the art can know many suitable methods for adoptive therapy (eg, Rosenberg et al., (2008) Nat Rev Cancer 8(4): 299-308).
  • the present invention also relates to a method for treating and/or preventing AFP-related diseases in a subject, which includes the step of adoptively transferring AFP-specific T cells to the subject.
  • the AFP-specific T cells can recognize the FMNKFIYEI-HLA A0201 complex.
  • the AFP-specific T cells of the present invention can be used to treat any AFP-related diseases that present the AFP antigen short peptide FMNKFIYEI-HLA A0201 complex. Including but not limited to tumors such as hepatocellular carcinoma.
  • the present invention provides a method for the treatment of AFP-related diseases, which includes the isolated T cell expressing the TCR of the present invention, preferably, the T cell is derived from the patient itself and transferred into the patient.
  • AFP-related diseases which includes the isolated T cell expressing the TCR of the present invention, preferably, the T cell is derived from the patient itself and transferred into the patient.
  • it includes (1) isolating T cells from patients, (2) transducing T cells in vitro with nucleic acid molecules of the present invention or nucleic acid molecules capable of encoding TCR molecules of the present invention, and (3) transducing genetically engineered T cells into patients in vivo.
  • the number of cells to be isolated, transfected, and reinfused can be determined by the physician.
  • the TCR of the present invention can bind to the AFP antigen short peptide complex FMNKFIYEI-HLA A0201, and the cells transduced with the TCR of the present invention can be specifically activated and have a strong killing effect on target cells.
  • the synthetic short peptide FMNKFIYEI (SEQ ID NO.: 9; Beijing Saibaisheng Gene Technology Co., Ltd.) was used to stimulate peripheral blood lymphocytes (PBL) from healthy volunteers with genotype HLA-A0201.
  • the FMNKFIYEI short peptide was renatured with biotin-labeled HLA-A0201 to prepare pHLA haploid. These haploids are combined with PE-labeled streptavidin (BD Company) to form a PE-labeled tetramer, and the tetramer and anti-CD8-APC double positive cells are sorted. Amplify the sorted cells, and perform secondary sorting according to the above method, and then use the limiting dilution method for monoclonal. Monoclonal cells were stained with tetramers, and the screened double positive clones are shown in Figure 3.
  • the function and specificity of the T cell clone were further tested by ELISPOT experiment.
  • Those skilled in the art are familiar with the method of using ELISPOT assay to detect cell function.
  • the effector cells used in the IFN- ⁇ ELISPOT experiment of this example are the T cell clones obtained in the present invention, the target cells are T2 cells loaded with the short peptides of the present invention, and the control group is T2 cells loaded with other short peptides and without any Short peptide T2 cells.
  • the procedure of the ELISPOT experiment is as follows: Add the test components to the ELISPOT plate in the following order: 40 ⁇ l T2 cells 5 ⁇ 10 5 cells/ml (ie 20,000 T2 cells/well), 40 ⁇ l effector cells (2000 cells) After T cell cloning/well), the experimental group was added with 20 ⁇ l of specific short peptide, the control group was added with 20 ⁇ l of non-specific short peptide, and the blank group was added with 20 ⁇ l of culture medium (test medium), and set up 2 replicate holes. Then incubate overnight (37°C, 5% CO 2 ). Subsequently, the plate was washed and subjected to secondary detection and color development.
  • the plate was dried for 1 hour, and then the spots formed on the membrane were counted with an immunospot plate reader (ELISPOT READER system; AID company).
  • ELISPOT READER system immunospot plate reader
  • Figure 14 The obtained specific antigen-specific T cell clones have specific responses to T2 cells loaded with short peptides of the present invention, but basically no response to other unrelated peptides and T2 cells not loaded with short peptides.
  • the cDNA synthesis uses clontech’s SMART RACE cDNA amplification kit, and the primers used are designed in the C-terminal conserved region of the human TCR gene.
  • the sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is a complementary sequence and does not contain introns. After sequencing, the structure of the ⁇ chain and ⁇ chain sequence of the TCR expressed by the double-positive clone is shown in Figure 1 and Figure 2, respectively.
  • FIG 1a, Figure 1b, Figure 1c, Figure 1d, Figure 1e and Figure 1f respectively show the TCR ⁇ chain.
  • Figure 2a, Figure 2b, Figure 2c, Figure 2d, Figure 2e and Figure 2f are the TCR ⁇ chain variable domain amino acid sequence, TCR ⁇ chain variable domain nucleotide sequence, TCR ⁇ chain amino acid sequence, TCR ⁇ chain nucleotide sequence, and leader sequence. TCR ⁇ chain amino acid sequence and TCR ⁇ chain nucleotide sequence with leader sequence.
  • the ⁇ chain contains CDRs with the following amino acid sequence:
  • the full-length genes of TCR alpha chain and beta chain were cloned into the lentiviral expression vector pLenti (addgene) by overlap PCR. Specifically: using overlap PCR to connect the full-length genes of the TCR ⁇ chain and the TCR ⁇ chain to obtain the TCR ⁇ -2A-TCR ⁇ fragment.
  • the lentiviral expression vector and TCR ⁇ -2A-TCR ⁇ are digested and connected
  • pLenti-TRA-2A-TRB-IRES-NGFR plasmid As a control, a lentiviral vector pLenti-eGFP expressing eGFP was also constructed. Then use 293T/17 to package the fake virus.
  • Example 3 The expression, refolding and purification of AFP antigen short peptide specific soluble TCR
  • the ⁇ and ⁇ chains of the TCR molecule of the present invention may respectively only contain the variable domain and part of the constant domain, and a cysteine residue is introduced into the constant domains of the ⁇ and ⁇ chains.
  • the positions of introducing cysteine residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotide of its ⁇ chain The sequences are shown in Figure 4a and Figure 4b, respectively, and the amino acid sequence and nucleotide sequence of the ⁇ chain are shown in Figure 5a and Figure 5b, respectively.
  • the target gene sequences of the above-mentioned TCR ⁇ and ⁇ chains were synthesized and inserted into the expression vector pET28a+(Novagene) by the standard method described in the “Molecular Cloning Laboratory Manual” (third edition, Sambrook and Russell). ), the upstream and downstream cloning sites are NcoI and NotI respectively. The inserted fragment was confirmed by sequencing.
  • the ⁇ and ⁇ chains of TCR were expressed
  • the inclusion bodies formed later were extracted by BugBuster Mix (Novagene) and washed repeatedly with BugBuster solution.
  • the inclusion bodies were finally dissolved in 6M guanidine hydrochloride, 10mM dithiothreitol (DTT), 10mM ethylenediaminetetraacetic acid (EDTA) ), 20mM Tris (pH 8.1).
  • the dissolved TCR ⁇ and ⁇ chains are quickly mixed with 5M urea, 0.4M arginine, 20mM Tris (pH 8.1), 3.7mM cystamine, 6.6mM ⁇ -mercapoethylamine (4°C) at a mass ratio of 1:1, and the final concentration is 60mg/mL.
  • 5M urea 20mM Tris (pH 8.1)
  • 20mM Tris 20mM Tris (pH 8.1)
  • cystamine 6.6mM ⁇ -mercapoethylamine
  • 4°C a mass ratio of 1:1
  • the solution is filtered by a 0.45 ⁇ M filter membrane and purified by an anion exchange column (HiTrap Q HP, 5ml, GE Healthcare).
  • the eluted peak contains the TCR of the successfully renatured ⁇ and ⁇ dimers and confirmed by SDS-PAGE gel.
  • TCR was then further purified by gel filtration chromatography (HiPrep 16/60, Sephacryl S-100HR, GE Healthcare). The purity of the purified TCR was determined by SDS-PAGE to be greater than 90%, and the concentration was determined by the BCA method.
  • the SDS-PAGE gel image of the soluble TCR obtained by the present invention is shown in FIG. 6.
  • variable domains of the TCR ⁇ and ⁇ chains in Example 2 were constructed into a stable soluble single-chain TCR molecule connected by a flexible short peptide (linker) by using the method of site-directed mutagenesis.
  • the amino acid sequence and nucleotide sequence of the single-stranded TCR molecule are shown in Figure 7a and Figure 7b, respectively.
  • the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 8a and Figure 8b, respectively; the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 9a and Figure 9b, respectively; its linker The amino acid sequence and nucleotide sequence of the sequence are shown in Figure 10a and Figure 10b, respectively.
  • the target gene was digested with NcoI and NotI, and then connected to the pET28a vector digested with NcoI and NotI.
  • the ligation product was transformed into E.coli DH5 ⁇ , spread on an LB plate containing kanamycin, and incubated overnight at 37°C. Positive clones were selected for PCR screening, the positive recombinants were sequenced, and the recombinant plasmids were extracted after confirming the correct sequence.
  • E.coli BL21(DE3) for expression.
  • the inclusion bodies were dissolved in a buffer (20mM Tris-HCl pH 8.0, 8M urea), centrifuged at a high speed to remove insoluble materials, the supernatant was quantified by BCA method and then aliquoted and stored at -80°C for later use.
  • refolding buffer 100mM Tris-HCl pH 8.1, 0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM ⁇ -mercapthoethylamine, 1.87mM Cystamine
  • refolding buffer 100mM Tris-HCl pH 8.1, 0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM ⁇ -mercapthoethylamine, 1.87mM Cystamine
  • the collected elution fractions were analyzed by SDS-PAGE, and the fractions containing single-stranded TCR were concentrated and further purified with a gel filtration column (Superdex 75 10/300, GE Healthcare), and the target fractions were also analyzed by SDS-PAGE.
  • the eluted fractions used for BIAcore analysis were further tested for purity by gel filtration.
  • the conditions are: Column Agilent Bio SEC-3 (300A, 7.8 ⁇ 300mm), the mobile phase is 150mM phosphate buffer, the flow rate is 0.5mL/min, the column temperature is 25°C, and the UV detection wavelength is 214nm.
  • the SDS-PAGE gel image of the soluble single-chain TCR obtained in the present invention is shown in FIG. 11.
  • the BIAcore T200 real-time analysis system was used to detect the binding activity of the TCR molecules obtained in Example 3 and Example 5 with the FMNKFIYEI-HLA A0201 complex.
  • the synthetic short peptide FMNKFIYEI (Beijing Saibaisheng Gene Technology Co., Ltd.) was dissolved in DMSO to a concentration of 20 mg/ml.
  • the inclusion bodies of the light chain and the heavy chain were dissolved with 8M urea, 20mM Tris pH 8.0, 10mM DTT, and 3M guanidine hydrochloride, 10mM sodium acetate, 10mM EDTA were added before renaturation to further denature.
  • FMNKFIYEI peptide at 25mg/L (final concentration) to refolding buffer (0.4M L-arginine, 100mM Tris pH 8.3, 2mM EDTA, 0.5mM oxidized glutathione, 5mM reduced glutathione, 0.2mM PMSF, cooled to 4°C), then add 20mg/L light chain and 90mg/L heavy chain (final concentration, heavy chain is added in three times, 8h/time), and renaturate at 4°C for at least 3 days Upon completion, SDS-PAGE will test whether the refolding is successful.
  • refolding buffer 0.4M L-arginine, 100mM Tris pH 8.3, 2mM EDTA, 0.5mM oxidized glutathione, 5mM reduced glutathione, 0.2mM PMSF, cooled to 4°C
  • the protein-containing fractions were combined, concentrated with a Millipore ultrafiltration tube, the protein concentration was determined by BCA method (Thermo), and the protease inhibitor cocktail (Roche) was added to store the biotinylated pMHC molecules in aliquots at -80°C.
  • the soluble TCR molecules of the present invention and the kinetic profiles of the combination of the soluble single-chain TCR molecules constructed by the present invention and the FMNKFIYEI-HLA A0201 complex are shown in Figure 12 and Figure 13, respectively.
  • the map shows that both the soluble TCR molecules and soluble single-chain TCR molecules obtained in the present invention can bind to the FMNKFIYEI-HLA A0201 complex.
  • the above method was used to detect the binding activity of the soluble TCR molecule of the present invention with several other unrelated antigen short peptides and HLA complexes, and the results showed that the TCR molecule of the present invention did not bind to other unrelated antigens.
  • Example 7 Activation experiment of T cells transduced with TCR of the present invention on T2 loaded target cells
  • the following experiments were performed to prove the specific activation response of T cells transduced by TCR of the present invention to target cells.
  • the IFN- ⁇ production detected by the ELISPOT test was used as the readout value of T cell activation.
  • Test medium 10% FBS (Gibco, catalog number 16000-044), RPMI 1640 (Gibco, catalog number C11875500bt)
  • PVDF ELISPOT 96-well plate (Merck Millipore, catalog number MSIPS4510)
  • Human IFN- ⁇ ELISPOT PVDF-Enzyme Kit contains all the other reagents needed (capture and detection antibody, streptavidin-alkaline phosphatase and BCIP/NBT solution)
  • the target cells used in this experiment are T2 cells loaded with specific short peptides. Prepare target cells in the experimental medium: adjust the concentration of target cells to 2.0 ⁇ 10 5 cells/ml, and take 100 microliters per well to obtain 2.0 ⁇ 10 4 cells/well.
  • the effector cells (T cells) in this experiment are CD8 + T cells expressing the TCR specific for the AFP antigen short peptide of the present invention, and the same volunteer's CD8 + T not transfected with the TCR of the present invention is used as a control group.
  • Stimulate T cells with anti-CD3/CD28 coated beads (T cell amplification, life technologies), and transduce them with a lentivirus carrying a short peptide specific TCR gene of AFP antigen, containing 50IU/ml IL-2 and 10ng/ml IL-7 was expanded in 1640 medium containing 10% FBS until 9-12 days after transduction, and then these cells were placed in the test medium and centrifuged at 300g room temperature for 10 minutes to wash. The cells are then resuspended in the test medium at 2 ⁇ the desired final concentration.
  • the negative control effector cells were treated in the same way.
  • the well plates as follows: Dilute the anti-human IFN- ⁇ capture antibody 1:200 with 10 ml of sterile PBS per plate, and then add 100 ⁇ l of the diluted capture antibody to each well. . Incubate the plate overnight at 4°C. After incubation, wash the well plate to remove excess capture antibody. Add 100 ⁇ l/well of RPMI 1640 medium containing 10% FBS, and incubate the plate at room temperature for 2 hours to seal the plate. The medium is then washed away from the well plate, and any residual wash buffer is removed by flicking and tapping the ELISPOT well plate on the paper.
  • test components added to the ELISPOT plate in the following order:
  • target cells 100 microliters of target cells 2*10 5 cells/ml (total about 2*10 4 target cells/well).
  • effector cells 1*10 4 control effector cells/well and AFP TCR positive T cells/well.
  • Dilute streptavidin-alkaline phosphatase 1:100 with PBS containing 10% FBS add 100 microliters of diluted streptavidin-alkaline phosphatase to each well and incubate the plate at room temperature 1 hour. Then wash 4 times with washing buffer and 2 times with PBS, tap the well plate on a paper towel to remove excess washing buffer and PBS. After washing, add 100 ⁇ l/well of BCIP/NBT solution provided by the kit for development. During development, cover the orifice plate with tin foil to protect from light, and let it stand for 5-15 minutes. During this period, routinely check the spots of the developing well plate to determine the best time to terminate the reaction.
  • the ELISPOT experiment (as described above) was used to test the IFN- ⁇ release of T cells transduced with the TCR of the present invention in response to target cells loaded with the AFP antigen short peptide FMNKFIYEI.
  • the results of the experiment are shown in Figure 15.
  • the T cells transduced with the TCR of the present invention have a very good activation response to the target cells loaded with its specific short peptide, while the T cells not transduced with the TCR of the present invention have little to the corresponding target cells. Activate the response.
  • Example 8 Elispot activation experiment of T cells transduced with TCR of the present invention on tumor cell lines
  • This example verifies that the effector cells transfected with the TCR of the present invention have a good specific activation effect on target cells.
  • the function and specificity of the TCR of the present invention in cells are tested by ELISPOT experiment.
  • the effector cell used in this example is PBL.
  • the experimental group used the TCR of the present invention to transfect PBL isolated from the blood of healthy volunteers.
  • the control group was PBL transfected with other TCRs.
  • the tumor cell line used in this example is HCCC9810-AFP (overexpressing AFP antigen) as a positive tumor cell line, and Huh-7, Huh-1HCCC9810 and SNU-398 as a negative tumor cell line.
  • ELISPOT plate was activated and coated with ethanol at 4°C overnight. On the first day of the experiment, remove the coating solution, wash and block, incubate for two hours at room temperature, remove the blocking solution, and add the test components to the ELISPOT plate: target cells are 20,000/well, and effector cells are 1,000/well. Hole (calculated according to the positive rate of transfection), and set up two duplicate holes. Incubate overnight (37°C, 5% CO2). On the second day of the experiment, the plate was washed and subjected to secondary detection and color development, and the plate was dried, and then the spots formed on the membrane were counted with an immunospot plate reader (ELISPOT READER system; AID20 company).
  • ELISPOT READER system an immunospot plate reader
  • the experimental results are shown in Fig. 16.
  • the effector cells transfected with the TCR of the present invention have a very good specific activation effect on the target cells, while the cells transfected with other TCRs have basically no activation effect on the positive target cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)

Abstract

La présente invention concerne un récepteur des Lymphocytes T (TCR) capable de se lier spécifiquement à un peptide court FMNKFIYEI dérivé d'un antigène AFP, un complexe pouvant être formé par le peptide court FMNKFIYEI et HLA A0201 et être présenté à la surface cellulaire conjointement avec le peptide court. La présente invention concerne également une molécule d'acide nucléique codant pour le TCR et un vecteur contenant la molécule d'acide nucléique. De plus, la présente invention concerne également une cellule pour la transduction du TCR selon la présente invention.
PCT/CN2019/099279 2019-08-05 2019-08-05 Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp WO2021022447A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/099279 WO2021022447A1 (fr) 2019-08-05 2019-08-05 Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/099279 WO2021022447A1 (fr) 2019-08-05 2019-08-05 Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp

Publications (1)

Publication Number Publication Date
WO2021022447A1 true WO2021022447A1 (fr) 2021-02-11

Family

ID=74502474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/099279 WO2021022447A1 (fr) 2019-08-05 2019-08-05 Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp

Country Status (1)

Country Link
WO (1) WO2021022447A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892629A4 (fr) * 2018-11-14 2022-11-16 XLifeSc, Ltd. Tcr à haute affinité pour la reconnaissance d'afp
WO2022262835A1 (fr) * 2021-06-18 2022-12-22 香雪生命科学技术（广东）有限公司 Tcr pour identifier un antigène afp et séquence codant pour celui-ci
WO2022262842A1 (fr) * 2021-06-18 2022-12-22 香雪生命科学技术（广东）有限公司 Récepteur de lymphocytes t à haute affinité pour antigène afp

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105255834A (zh) * 2010-09-20 2016-01-20 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN105408353A (zh) * 2013-07-26 2016-03-16 艾达普特免疫有限公司 T细胞受体
CN110343166A (zh) * 2018-04-03 2019-10-18 广东香雪精准医疗技术有限公司 识别afp抗原短肽的t细胞受体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105255834A (zh) * 2010-09-20 2016-01-20 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN105408353A (zh) * 2013-07-26 2016-03-16 艾达普特免疫有限公司 T细胞受体
CN110343166A (zh) * 2018-04-03 2019-10-18 广东香雪精准医疗技术有限公司 识别afp抗原短肽的t细胞受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GERRY, ANDREW ET AL.: "Targeting Alpha Fetoprotein with TCR Engineered T Cells in HCC", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 15, 11 May 2017 (2017-05-11) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892629A4 (fr) * 2018-11-14 2022-11-16 XLifeSc, Ltd. Tcr à haute affinité pour la reconnaissance d'afp
WO2022262835A1 (fr) * 2021-06-18 2022-12-22 香雪生命科学技术（广东）有限公司 Tcr pour identifier un antigène afp et séquence codant pour celui-ci
WO2022262842A1 (fr) * 2021-06-18 2022-12-22 香雪生命科学技术（广东）有限公司 Récepteur de lymphocytes t à haute affinité pour antigène afp

Similar Documents

Publication Publication Date Title
JP7452880B2 (ja) Ｓｓｘ２抗原を識別するｔ細胞受容体
WO2021068938A1 (fr) Récepteur de lymphocytes t reconnaissant une mutation kras et séquence de codage associée
WO2017076308A1 (fr) Tcr pour identifier un oligopeptide d'antigènes ny-eso-1
WO2016177339A1 (fr) Récepteur des lymphocytes t pour reconnaître des polypeptide à chaîne courte d'antigène ny-eso-1
CN106749620B (zh) 识别mage-a1抗原短肽的t细胞受体
WO2020024915A1 (fr) Récepteur de lymphocytes t pour identifier un antigène afp
CN110343166B (zh) 识别afp抗原短肽的t细胞受体
WO2021170115A1 (fr) Récepteur de lymphocytes t reconnaissant le hpv
WO2021139698A1 (fr) Récepteur de lymphocytes t pour l'identification d'un antigène de hpv et séquence codante associée
WO2021022447A1 (fr) Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp
WO2021016887A1 (fr) Récepteur de lymphocytes t reconnaissant le peptide court de l'antigène ssx2
CN109575121B (zh) 识别afp抗原短肽的t细胞受体
WO2021170117A1 (fr) Récepteur de lymphocytes t reconnaissant un peptide court d'antigène afp et séquence de codage de celui-ci
WO2021170116A1 (fr) Récepteur de lymphocytes t reconnaissant l'afp
WO2016177195A1 (fr) Récepteur des cellules t permettant de reconnaître le polypeptide à chaîne courte de l'antigène rhamm
WO2021139699A1 (fr) Récepteur de lymphocytes t pour la reconnaissance de l'afp et séquence codante associée
CN110627894B (zh) 识别ny-eso-1抗原短肽的t细胞受体及其编码序列
CN110577590B (zh) 一种识别afp抗原的tcr及其编码核酸
WO2022262835A1 (fr) Tcr pour identifier un antigène afp et séquence codant pour celui-ci
WO2021035446A1 (fr) Récepteur de lymphocytes t pour la reconnaissance d'un peptide court d'antigène afp et séquence de codage de celui-ci
WO2022206861A1 (fr) Récepteur de lymphocytes t pour l'identification d'afp
WO2022166904A1 (fr) Récepteur de lymphocytes t pour identifier l'hpv
CN110272483B (zh) 识别sage1抗原短肽的t细胞受体
CN116135878A (zh) 一种识别afp抗原的tcr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19940497

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19940497

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.10.2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19940497

Country of ref document: EP

Kind code of ref document: A1